Erbitux patent dispute ends in $120 million deal
The worldwide Erbitux patent dispute reached the end of the road with a settlement between the parties last week
ImClone Systems and Sanofi-Aventis agreed to settle a row with Yeda Research Development Corporation over the ownership of the patent for the cancer drug on Friday.
The dispute has been raging worldwide since the patent, number 6,217,866, was granted by...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.